Sarepta Therapeutics (SRPT) Net Equity Issued and Repurchased (2010 - 2020)

Sarepta Therapeutics' Net Equity Issued and Repurchased history runs 11 years deep, the most recent figure standing at -$4.3 million for Q2 2020.

• In Q2 2020, Net Equity Issued and Repurchased fell 4914.61% year-over-year to -$4.3 million; the TTM figure through Dec 2024 stood at -$4.3 million (changed N/A YoY), while the FY2025 annual figure was $20.0 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q2 2020 stood at -$4.3 million, down from $316.3 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $470.4 million in Q4 2018, with the low at -$4.3 million in Q2 2020.
• The 5-year median for Net Equity Issued and Repurchased is $10.6 million (2018), against an average of $119.4 million.
• The sharpest annual moves came in 2016 and 2020: Net Equity Issued and Repurchased surged 7634.47% in 2016, then tumbled 4914.61% in 2020.
• Sarepta Therapeutics' Net Equity Issued and Repurchased stood at -$149000.0 in 2016, then soared by 234914.09% to $349.9 million in 2017, then jumped by 34.44% to $470.4 million in 2018, then plunged by 100.0% to $1000.0 in 2019, then slumped by 428600.0% to -$4.3 million in 2020.
• Business Quant data shows SRPT's Net Equity Issued and Repurchased at -$4.3 million in Q2 2020, $316.3 million in Q1 2020, and $1000.0 in Q4 2019.